Focused on the discovery of new treatments for under-served skin diseases

The world-wide dermatology market is expected to grow to $22.7 billion by 2017 with the key drivers of growth being driven by innovation in chronic disease states such as psoriasis. Our compound is a first-in-class proteasome inhibitor for the treatment of rosacea and other topical skin diseases. It offers the potential to transform the value of the rosacea market through innovation to one of the largest segments in the dermatology market. Additionally the compound has promise as a therapeutic targeting Psoriasis, Skin aging, Acne, by breaking the inflammatory cascade associated with these disease states.

​

The combined estimated market potential for our compound is expected to exceed $500 million dollars in US sales annually

Rosacea is a dermato-ophthalmic condition that affects approximately 43 million in the US and Europe. It primarily affects the face and eyes and is characterized by the appearance of inflammatory lesions (papules and pustules), erythema (skin redness), and telandiectasia (spider veins). If all out progress tomorrow it is severe condition, rosacea can cause itching, pain and thickening of the skin.

Without treatment it may progress into a severe skin condition that can cause itching, pai, and thickening of the skin. No current therapeutics inhibit the transcription factor nuclear factor kappa beta (NFkB), which is a potent mediator of inflammation associated with rosacea.